Skip to content

    Excel Industries

    EXCELINDUS
    Chemicals·16 May 2025
    Management Summary

    Excel Industries delivered strong financial performance in Q4 and FY25, marked by significant revenue and EBITDA growth driven by improved demand and product mix. The company is strategically investing in capacity expansion for biocides, establishing a new R&D center, and commencing a long-term supply contract to drive future growth. While navigating a volatile market, Excel maintains a focus on operational efficiency and strengthening its core phosphorus chemistry business while diversifying into specialty chemicals.

    Highlights

    5
    • Q4 FY25 standalone revenue increased by 26% quarter-on-quarter to ₹248 crores, supported by uptake in the agrochemical sector.

    • Q4 FY25 standalone EBITDA grew by 61% quarter-on-quarter to ₹20 crores, with EBITDA margins improving to 8% from 6.3% in Q3 FY25.

    • FY25 standalone net operating revenues grew by 18% to ₹978 crores, and EBITDA surged by 400% to ₹121 crores, with margins at 12.3%.

    • Profit after tax for FY25 stood at ₹84 crores, a 453% increase from ₹15 crores in FY24.

    • Secured a long-term supply contract with a multinational company, with supplies expected to commence from Q2 of this financial year.

    Concerns

    3
    • The general environment of volatility continued with sudden changes in demand patterns, making future predictions difficult.

    • The agrochemical sector has experienced a severe destocking cycle and excess capacities in the last two years, impacting top line and margins.

    • Product cyclicity is a constant factor in the company's products, requiring continuous management of working capital and supply chain.

    Key financials

    Metrics

    8

    Periods

    2

    Q4 FY25

    4
    • Revenue
      ₹248 Cr
      QoQ+26%
    • EBITDA
      ₹20 Cr
      QoQ+61%
    • EBITDA Margin
      8%
    • PAT
      ₹11 Cr

    FY25

    4
    • Revenue
      ₹978 Cr
      YoY+18%
    • EBITDA
      ₹121 Cr
      YoY+4%
    • EBITDA Margin
      12.3%
    • PAT
      ₹84 Cr
      YoY+4.5%

    Segment breakdown

    Agrochemical Intermediates
    50% Share of Portfolio
    Specialty Chemicals
    20% Share of Portfolio
    Polymer Additives
    5% Share of Portfolio
    Pharma Intermediates and API
    4% Share of Portfolio
    Phosphorus-based Chemistry
    80% Share of Revenues
    Environment Business
    100% Share of Total Revenues
    List

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Capex

    ₹200 crores

    largely done through internal accruals

    Liquidity

    Liquidity disclosed

    Company has a strong balance sheet currently.

    Guidance & targets

    6
    CategoryTargetPriority
    Profitability
    EBITDA Margin
    13% to 15%
    High
    Capacity
    Biocide Capacity Expansion
    completed
    High
    Revenue
    Long-term Supply Contract Supplies
    start
    High
    Operations
    New Corporate R&D Center Operationalization
    operationalized
    High
    Capex
    Total Capital Expenditure
    ₹200-300 crores
    High
    Capex
    Asset Turnover for Future Growth CAPEX
    1.25 to 1.5 times
    Medium

    Long-term Supply Contract Commencement

    Q2 FY26
    CurrentCommissioning and production trials completed
    TargetSupplies started

    Why it matters

    Verifies the start of a new revenue stream from a strategic partnership, indicating execution of growth plans.

    supplies are expected to start from Q2 of this financial year.

    How to verify

    guidance_and_targets

    Risks & concerns

    4
    RiskSeverity

    Volatile market environment and demand patterns

    The general environment of volatility continued with sudden changes in demand patterns, making future predictions difficult.Management acknowledged

    medium

    Destocking cycle and excess capacities in agrochemical sector

    The agrochemical sector has experienced a severe destocking cycle and excess capacities in the last two years, impacting top line and margins.Management acknowledged

    medium

    Product cyclicity

    There is definite cyclicity in our products, which reflects in numbers over the years, requiring active management.Management acknowledged

    medium

    Chinese competition/dumping

    Analyst raised concerns about China's impact on pricing and excess glut. Management acknowledged Chinese competition but stated limited direct supply chain exposure and focus on being a preferred supplier.Analyst acknowledged

    medium

    Q&A highlights

    8

    “Going forward, it's difficult to say because of the volatile environment, and all of the circumstances and situation. But are definitely some stabilization has come in and we will have to wait and watch to see how things are going forward.”

    Analyst sought clarity on demand revival and pricing stability in agrochemicals, a key segment, given past volatility. Management acknowledged stabilization but remained cautious on future outlook.

    asked by S. Padmanabhan

    2 min read6 chapters

    Detailed Narrative

    01

    Robust Financial Performance in FY25

    Excel Industries demonstrated strong financial recovery in FY25, with net operating revenues growing 18% year-over-year to ₹978 crores, up from ₹826 crores in FY24. This growth was significantly driven by volume. EBITDA saw a remarkable 400% increase to ₹121 crores, leading to an improved EBITDA margin of 12.3% for the full year, compared to 2.9% in FY24. Profit after tax also surged by 453% to ₹84 crores, reflecting enhanced operational efficiency and demand revival.

    02

    Strategic Focus on Specialty Chemicals and Diversification

    The company has successfully transitioned into a specialty chemicals entity, with agrochemical intermediates now comprising 50-60% of its portfolio, specialty chemicals 20-30%, polymer additives 5-8%, and pharma intermediates/API 4-8%. While phosphorus chemistry remains a core strength, accounting for 80% of revenues, Excel is actively developing a portfolio of biocides and exploring other chemistries to diversify its product offerings and reduce concentration risks. This strategy aims to leverage existing technical capabilities and market positions.

    03

    Key Growth Initiatives and Capacity Expansion

    Excel Industries is executing several strategic growth initiatives. A capacity expansion for one of its biocides is underway, involving an investment of ₹10.3 crores to double its capacity, with completion expected by H2 FY26. The company has also secured a long-term supply contract with a multinational company, with supplies projected to commence in Q2 FY26. Furthermore, a new corporate R&D center, requiring approximately ₹15 crores in capital expenditure, is targeted to be operational in H1 FY26 to bolster innovation and product development.

    04

    Capital Expenditure Plans and Funding Strategy

    The company plans a significant capital expenditure of ₹200-300 crores over the next three years. This investment will be allocated towards both essential maintenance and modernization, typically ₹40-50 crores annually, as well as growth-oriented opportunities. The funding for these investments will primarily come from internal accruals, supported by the company's strong balance sheet. The future growth capex is expected to yield an asset turnover of 1.25 to 1.5 times.

    05

    Market Outlook and Risk Management

    Management acknowledged the persistent volatility in the market environment and demand patterns, particularly in the agrochemical sector, but noted signs of stabilization. The company's strategy involves navigating these uncertainties through agile production, constant emphasis on volumes and market share, and prudent working capital management. Despite Chinese competition, Excel maintains a very limited direct supply chain exposure to China and focuses on being a preferred supplier in its key product segments.

    06

    Commitment to Sustainability and Operational Excellence

    Excel Industries emphasizes health, safety, and environment management, with 48% of its total electricity requirements sourced from renewable sources. The company aims to maintain EBITDA margins between 13% and 15% in the medium term by focusing on operational efficiency, optimizing product mix, and strengthening its presence in high-margin specialty chemicals. This commitment underpins a resilient and sustainable business model.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.